(Source: Actelion Ltd) Investor webcast to provide background information on Actelion's new DORA to be broadcast 07 July 2016 at 14:00 hrs CEST ALLSCHWIL, SWITZERLAND - 07 July 2016 - Actelion Ltd (SIX: ATLN) announced today that the company is initiating a Phase II program with its new dual orexin receptor antagonist (DORA) in patients with insomnia. The decision to move into a Phase II program is based on excellent data collected from the preclinical and Phase I clinical program, as well as a thorough understanding of the potential of dual orexin receptor antagonism on sleep efficacy and architecture. Information gathered on the optimal profile for a DORA has resulted in the discovery of a...
↧